Rajaram N, Tatake R J, Advani S H, Gangal S G
Immunology Division, Cancer Research Institute, Parel, Bombay, India.
Br J Cancer. 1990 Aug;62(2):205-8. doi: 10.1038/bjc.1990.261.
We report the natural killer (NK) and lymphokine activated killer (LAK) cell activities in peripheral blood lymphocytes (PBL) from untreated patients with Hodgkin's disease (HD) and from healthy donors. The frequency of LAK cell precursors was also studied using limiting dilution analysis (LDA). About 75% of the HD patients had normal NK activity. There was a higher percentage of low NK responders (mean percent NK activity of healthy donors--2 SD) in patients with lymphocyte depletion histologic grade of the disease and those who were in clinical stage IV, suggesting a correlation of decrease in NK activity with poor prognosis. We found efficient LAK activity against the NK-sensitive K562 cells and NK-resistant VIP (melanoma) and T-24 (bladder carcinoma) tumour targets in both low and normal NK responder HD patients, irrespective of the histopathological grade and clinical stage of the disease. In concordance with their good LAK cell activity, HD patients showed a frequency distribution of LAK cell progenitors in the PBL comparable to that of healthy donors.
我们报告了未经治疗的霍奇金淋巴瘤(HD)患者和健康供者外周血淋巴细胞(PBL)中的自然杀伤(NK)细胞和淋巴因子激活的杀伤(LAK)细胞活性。还使用极限稀释分析(LDA)研究了LAK细胞前体的频率。约75%的HD患者NK活性正常。在疾病的淋巴细胞消减组织学分级患者和临床IV期患者中,低NK反应者(健康供者NK活性的平均百分比-2标准差)的比例更高,这表明NK活性降低与预后不良相关。我们发现,无论疾病的组织病理学分级和临床分期如何,低NK反应者和正常NK反应者的HD患者对NK敏感的K562细胞以及NK抗性的VIP(黑色素瘤)和T-24(膀胱癌)肿瘤靶标均具有有效的LAK活性。与它们良好的LAK细胞活性一致,HD患者PBL中LAK细胞祖细胞的频率分布与健康供者相当。